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SUMMARY
The large amount ofdata published over the last decade has drastically expanded our knowledge
on the biology of human cy4okines Moreover. more insight has been gained on the mechanism of
action of cytokines, stretching from cytokine receptor binding to induction of gene transcription
and the signaling routes in between As a consequence the involvement of cyokines in malignant
disease has been further acknowledged. Much attention has been focused on aberrant cy'tokine and
cytokine receptor expression in malignancies. Although cytokine-induced intracellular pathways
contribute to the identification of aberrantly activated signaling routes in malignancies, the
significance of these pathways in leukemogenesis/carcinogenesis is sti l l  largely unknown. ln
chapter two biological and clinical aspects of six cytokines, namely interleukin-l (lL-l), IL-3. lL-
4, IL-6, lL-9. and IL-10 were reviewed The review is mainly focused on the normal biological
function of the cytokines, with some attention directed towards the involvement of these cytokines
in hematological  mal ignancies
Chapter three describes the nature ofspontaneous IL-lB and IL-6 expression in blasts ofacute
myeloid leukemia (AML) patients. Constitutive xpression of IL-lB mRNA was observed in 8 out
of 19 AML cases, whereas spontaneous IL-6 mRNA occured in 7 cases Spontaneous IL- l B and lL-
6 expression could, at least partly, be explained by an enhanced in vilrc transcription rate of the
respective genes, when compared to the transcription rate of IL-lB and IL-6 in unstimulated, resting
monoc)'tes Moreover, constitutive cytokine expression was associated with constitutive binding
activity ofthe transcription factor nuclear factor-kappa B (NF-rB), which consisted ofboth p50 and
p65 subunits It is well established that NF-rB containing both p50 and p65 can be transcriptionally
active Constitutive NF-rB DNA binding activity could not be suppressed by the addition of anti-
lLi antibody, indicating that constitutive NF-rB occurs independently of an autocrine loop
mediated by lL-lB. These data demonstrate that spontaneous expression of cyokines in blasts of
AML cases is frequently associated with an enhanced cytokine gene trancription rate and ongoing
activation of the transcription factor NF-xB
In chapter four we further investigated the nature of constitutive lL-6 and IL- I expression in
AML Transient ransfection studies and gel retardation assays demonstrated that constitutive IL-6
promoter activity was associated not only with constitutive NF-rB DNA binding, but also with
constitutive binding activity of nuclear factor interleukin-6 (NF-IL6) and activator protein I (AP-l)
Both transcription factor binding activity and IL-6 promoter activity could still be upregulated byl
phorbol myristate acetate (PMA). indicating that constitutive expression can still be tur-ther
enhanced in these AML cases. Blasts obtained from seven patients with AML, selected on the basis
of their constitutive h vitro expression of the lL-l and It.-6 gene, were subjected to IL-4 treatlnent
in order to study the regulatory role ofIL-4 on the transcriptional ctivation ofthese cytokine genes
Previous tudies demonstrated an inhibit ive effect of IL-4 on cfiokine secretion and transcription
tactor DNA binding in activated healthy human monocytes
Thirdly, tL-4 has been shown to activate the PIi-kinase pathway, although the role of PII-kinase in
lL-4 signaling remains unclear (17) Recent studies in cell l ines have implicated the involvement of
the PII-kinase pathway in cell proliferation (18,19). Similarly, IL-4 may enhance PI3-kinase
activity in Al\4L blasts and consequently increase prolif'eration Evidence . for this hypothesis,
however, is sti l l  lacking
Finallv. binding of IL-4 to its receptor esults in the JAK-mediated tyrosine phosphorylation of
proteins belonging to the IL-4 signaling cascade, including Janus Kinase (JAK)1, JAK2, JAKI,
TYK2, insulin receptor substrate-l (IRS-l), IRS-2, and Stat6 (20,21) It can be speculated that lL-4-
induced Stat6 in AML blasts may induce proliferation. However, evidence tbr such a correlation
has yet to be found. To date, I l-4-mediated nuclear signaling by Stat6 has only been irnplicated in
lymphoid cell proliferation (22) In AML, constitutive Stat6 expression has not been described,
although constitutive xpression of Statl, Stat3, and Stat5 is generally found in 25o./o of AMI- cases
(23,24) For these Stat proteins a firnctional role in the process of leukemogenesis i sti lL
unidentif ied
Our results show an overall inhibitory effect of IL-4 on cltokine gene expression which coincided
with an enhanced proliferation in many AML cases. Because of its divergent effect on blast
proliferation it seems unlikely that clinical therapy with IL-4 can be used to directly suppress AML
blast prolif-eration
The putative novel Stat factor LIL-Stat (for LPS- and IL-l-inducible Stat) is constitutively
expressed in CD34 early hematopoietic cells and in a large number of AML cases (chapter six). In
mature monocytes and granr-rlocytes LIL-Stat cannot be detected. neither constitutive nor inducible
Based on recognition of the LIL-Stat protein by the antibody against he N-terminal site of Statl,
but not by the anti-StatlC-terminal ntibody, it can be hypothesized that LIL-Stat is transcribed
trom the Statl gene followed by alternative splicing For Statl and Stat3 alternatively spliced
isoforms have already been reported (StatlB and Stat3B, respectively) (25.26). The StatlB isoform
(8a kDa) binds the DNA equally well as its wild- type, but it is transcriptionally inactive (25)
StatlB rnay compete with Statlcr for binding the GAS elements within promoters and block
transcriptional ctivation by Statlcr Stat3B cDNA encodes a 83 kDa protein that has several
features that are distinct from StatSct (26) StatSB. for instance, can functionally interact with c-Jun,
whereas StatJct cannot (27) ln these studies overexpression of Stat3B constitutively activated the
Il-6-responsive lement of the cr2-microglobulin gene On the other hand. Stat38 has also been
decribed as a donrinant negative regulator of l l-5-induced StatS-mediated transcription (26)
Recently. two naturally occurring truncated isoforms of IL-4-induced Stat6 were described, Stat6b
and Stat6c (28) Both Stat6b and Stat6c behave as dominant negative Stat6 variants, that aflected
lL-4 mediated responses through differential transcriptional regulation However, considering the
following observations it seems unlikely that LIL-Stat is a carboxy-terminal truncated splice variant
of Statl: ( i) t-t l--Stat binds a gamma interferon activation (GAS)-site which is different from the
GAS-site recognized by Statl ln contrast. the splice variants StatlB, Statl8, and the Stat6b and
Stat6c isoforrns, bind GAS sequences also recognized by full length Statl, Stat3. and Stat6,
respectively (25,27,28) (i i) LIL-Stat is activated by diff-erent cytokines than those which enhance
Chapter twelve
binding activity.These data suggest that the LIL-Stat transcription factor is constitutively activated
in undifferentiated and leukemic hematopoietic cells, but not in mature cells, implicating a role for
this transcription f'actor in the process ofdifferentiation
ln chapter seven the regulation of IL-6 in freshly isolated healthy human monocltes was studied.
The results of the study demonstrate that, in contrast to earlier eports, IL-3 alone was incapable of
inducing IL-6 mRNA. Rather, IL-3 prirned monocytes to enhance the IL-6 mRNA expression when
costimulated with LPS The observed difference between IL-3 and LPS may be related to our
observation that IL-3 merely induced the p50 subunit of the transcription factor NF-rB. while LPS
induced both the p50 as well as the p65 subunit of NF-xB This was denronstrated with RNA
studies and Electrophoretic Mobility Shift Assays (EMSA) Ilowever, no difl'erence rvas tbund with
regard to the induction of AP-l and NF-IL6 alter treatment with either lL-3 oI LPS alone Priming
with lL-1, followed by I-PS stimulation resulted in a down-regulation of the DNA binding capacity
of AP-l and NF-rB and an upregulation of the NF-lL6 as compared to treatment with LPS alone
S inceAP- I  hasbeensugges tedasanega t i ve regu la to ro f t he lL -6geneexp ress ion , i t i s conce i vab le
that, after priming with IL-3. the reduced DNA binding activity of AP-1, in conjunction with the
increased DNA binding of NF-IL6 may synergistically enhance IL-6 mRNA expression
The transport of leukotriene C4 (L.TC4) in hernatopoietic cells is controlled by an ATP dependent
carrier encoded by the rnultidrug resistance proteinl (MRPI) gene whose function can be blocked
by the compound MK-571. Since LT's play a major role in control of cytokine expression in
monocytes, we investigated whether blocking of the MRPI mediated fi"rnction by N'lK-571 might
affect he production of IL-6 In chapter eight it was demonstrated that MK-571 stronqlv enhan-
ced IL-6 expression at mRNA and protein level in LPS- and IL-l- stimulated rnonocytes
Surprisingly, retention of LT's in the cytosol could not account for the elevated lL-6 protein
secretion Rather, the increase in IL-6 coincided with an MK-571-mediated increased phosphory-
lation of p38 rvithout afl 'ecting c-Jun-N terminal kinase (JNK) The p38. but also the ertracellular
s ignal - regulated k inase (ERK) l /2 s ignal ing cascade.  appeared to be involved in MK-571-enhanced
IL-6 protein secretion. EMSAs demonstrated that l\ ' lK-571 did not aft-ect the Il--l- or LPS-induced
DNA binding activity of AP- I and NF-rB but rather enhanced the transactivational activity of the
full length lL-6 promoter construct. This may be explained by an enhanced phosphorylation state of
the NF-xB and AP-l transcription factors and/or the enhanced activity of othel regulatory factors
such asNF-lL6 and cAN'lP responsir, 'e elentent binding protein (CREB), which uray be nrediated by
MK-571. These results suggest that the membrane transpofier MRPI is involved in the cytokine
regulation i  activated human monocytes
To explore the involvement of the different mitogen-activated protein kinase (MAPK) cascades in
the regulation of lL-6, t ieshly isolated monocy.tes were treated u,ith the serine/threonine protein
phosphatase inhibitor okadaic acid (OA) In chapter nine we show that OA-stimulated monocytes
secrete high levels of {L-6 protein, which coincides with enhanced bindin-e activity of NF-xB, as
well as rvith phosphorylation and activation of the MAPK rrrolecules ERKI/2 and JNK Although
Summary. General Discussion, and Future Perspectives
the rafl/MEKI/ERKI/2 pathway was involved in NF-rB-mediated lL-6 gene transcription, this
pathway did not afl'ect the NF-rB DNA-binding activity Rather, it enhanced the transcriptional
potency of NF-rB Blocking the MEKKl,4\4KK4/JNK pathway also suppressed NF-rB-dependent
Il.-6 promoter activity. In accordance with these observations, NF-rB-mediated gene transcription
depended on both serine kinase activity and on interaction with c-Jun protein. These data show that
OA-induced IL-6 gene expression in hurnan monocy.tes i , at least panly, mediated through the
ERKI/2 and JNK pathway-dependent activation of NF-rcB transcriptional capacity Furthermore,
these obsen'ations suggest that the JNK pathway may regulate NF-xB-mediated gene transcription
through its phosphorylation of c-Jun Subsequentlv, phosphorylated c-Jun may bind NF-rB to
errhance lL-o gene t ranscr ipt ion
Next. the possible involvement of the third M,,\PK cascade, the p3S/RK signaling route, in the
regulation of IL-6 in hurnan nronocltes was studied The results described in chapter ten clearly
demonstrate hat the phosphatase inhibitor OA is a potent activator of both p38 kinase activity and
of lL-6 gene transcription However, studies rvith the specific pharrnacological inhibitor 58203580
as rvell as with kinase-inactive mutants of MKK3 and MKK6 derronstrated that the p38 signal
transduction pathway is not involved in the regulation of lL-6 gene transcription ln contrast to the
lack of effect on transcriptional level, SB203580 potently inhibited OA-enhanced IL-6 protein
secretion from monocytes These data indicate that the p38 pathway affects lL-6 regulation at the
level of rnRNA stabil ization or at the translational level Subsequently. IL.-6 mRNA analysis
revealed that SB203580 exerts its inhibitory effect by rendering lL-6 transcripts less stable
Considering the important role for NF-xB in regulating cyokine gene transcription and its putative
involvement in attenuating apoptosis we investigated the role of the p38 kinase pathway in the
activation of NF-rB In chapter eleven the ervthroleukernic cell l ine TF-l was exposed to the p38
kinase inhibitor SB203580 prior to OA stirnulation At a concentration of lprM, 58201580 did not
affbct NF-rB DNA binding activity ln addition. S8201580 had no inhibitory efl-ect on either NF-
rcB-drive n gene transcription or GAL4p65-mediated promoter activity. Similar results were
obtained after the introduction of kinase-inactive mutants of MKK3 or MKK6, the upstream kinases
tionr p-38 Oi particular interest was the observation that S820i580 at concentrations of 5 anc
l0pM significantly enhanced NF-rB-driven promoter activity The increased NF-rB-rnediatec
gene transcription was preceded by the enhanced phosphorylation of both ERK and JNK
l'ransf-ection data using kinase-deficient modules belonging the different MAP kinase pathwayl
revealed that only S820i580-induced ERK activity contributed to the activation of NF-xB Thest
data dernonstrate hat the p38 pathway is not involved in NF-rB activation 58201580 at highe
concentrations activates the ERK kinases. possibly by cross-reactivity between the ditferent MAPI
signal transduction pathways. S8203.580-activated ERK subsequently enhances NF-KI
transcriotional cti l ' i tv
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GENERAL DISCUSSIoN
Although the cause of spontaneous expression of colony stimulating factors (CSFs) in AML cells is
largelyunknown, its involvement in autonomous proliferation is widely appreciated (l-6) Genomic
alterations in the different CSF genes and their prclmoters have rarely been observed and can
therefore not account for disregulated CSF gene expression With respect to the spontarreous
expression of GM-CSF, G-CSF and M-CSF it was previously demonstrated that modil lcations
primarily took place on the level of nRNA stabil ity (7) ln normal hematopoietic t issues growth
factor and cy'tokine mRNAs are extremely short-l ived with half-l ives ranging from less than 20
minutes to I hour. In different non-hematological tumor tissues it was previously shown that IL-6
and IL-l half-lives ranged from 2 to more than 8 hours whereas in their norrnal counterparts these
cytokine mRNAs had half-l ives of less than 20 minutes (8) The studies described in chapters 3,4,
and 5, dernonstrated that constitutive IL-6 and IL-l expression in AML blasts is frequently
associated with an enhanced transcription rate of the respective genes compared with the
transcription rate in healthy unstimulated monoc!.tes The Th2-type cyokine tL-4 appeared a good
candidate for suppressing cytokine gene expression and proliferation in AN4L since in healthy
monocltes IL-4 is known for its inhibitory effect on IL-i, lL-6, GM-CSF and G-CSF gene
regulation (9, l0). Moreover, lL-4 inhibits DNA binding activity of transcription factors relevant tbr
lL-6 and IL- l  gene expression.  such as NF-rB,  AP-1,  and NF-IL6 ( l l )  lndeed.  i t  was shown that
lL-4 demonstrated an overall suppressive effect on lL-1. tL-6. GN4-CSF, and G-CSF expression i
blasts of AML patients
Although IL-4 elicited an inhibitory effect on GM-CSF and G-CSF secretion. proliferation of these
AML blasts was in many cases enhanced rather than suppressed. Recent studies have also reported
on the divergent eft 'ects oflL-4, IL-10. and IL-13 on inTitro blast proliferation (12) ln these
studies the final effect of each cytokine (enhancement/inhibit ion/no effect) deperrded on the
individual patient and on the presence of other exogenous cytokines. Simiiar to our observations. all
three cytokines inhibited constitutive cytokine secretion bv AML blasts in these studies These
observations suggest that the efl 'ect of IL-4 on AML blast proliferaticln is in rnany cases uncoupled
from its inhibitory effect on cy4okine gene expresslon
Several observations in human healthy monocytes may help to explain why IL-4 generally inhibits
constitutive or induced c1'tokine xpression and at the same ti6e enhances prolit-eration i Al\1L
blasts.  F i rs t iy ,  IL-4 induces type I  and type I l  lL- l  receptor  ( lL- lRI  and lL- lRl l )  rnRNA levels in
monocl'tes, as well as IL-3Ra mRNA expression (13.14) It could be hypothesized that IL-'{
treatment of AML blasts may elevate the number of IL-l and/or l l--i receptors on the cell
membrane, rendering AML blasts more sensitive tothe proliferative activity of IL-l and/or lL--l
Secondly, it is observed that in monocytes IL-4 induces p38 kinase activity and subsequent
activation of MAPKAPK-2 (15) In a seperate study the p38 kinase pathwav was irnplicated in Il--
l -  and IL-3- induced pro l i f 'erat ion i  AML blasts (16)  Inhib i t ion of  the p38 MAP k inase bv the
specific pharmacological inhibitor SB203580 markedly reduced cytokine-induced blast
proliferation Although the effect of lL-4 on N{AP kinase activity has not been studied in AML. it
can be postulated that I l-4-induced p38 MAP kinase activity in AML rnay enhance blast
oroliferation
Thirdly, IL-4 has been shown to activate the PI3-kinase pathway, although the role of Pl3-kinase in
IL-4 signaling remains unclear (17) Recent studies in cell I ines have implicated the involvement of
the PI3-kinase pathway in cell proliferation (18, 19). Similarly, IL-4 may enhance Pl3-kinase
activity in AML blasts and consequently increase prolit-eration Evidence , for this hypothesis,
however. is sti l l  lacking.
Finally, binding of lL-4 to its receptor esults in the JAK-mediated tyrosine phosphorylation of
proteins belonging to the IL-4 signaling cascade, including Janus Kinase (JAK)1, JAK2, JAK3,
TYK2, insulin receptor substrate-1 (IRS-1), IRS-2, and Stat6 (20,21) It can be speculated that lL-4-
induced Stat6 in AML blasts may induce proliferation However. evidence fbr such a correlation
has yet to be lound To date, l l-4-nrediated nuclear signaling by Stat6 has only been implicated in
lynrphoid cell proliferation (22) In AML, constitutive Stat6 expression has not been described,
although constitutive xpression of Statl, Stat.l, and Stat5 is generally found in 25oto f AML cases
(23.24) For these Stat proteins a functional role in the process of leukemogenesis i  sti l l
unidentif ied.
Our results show an overall inhibitory effect of IL-4 on cytokine gene expression which coincided
with an enhanced proliferation in many AML cases. Because of its divergent effect on blast
proliferation it seerns unlikely that clinical therapy with IL-4 can be used to directly suppress AML
blast prolifbration
The putative novel Stat factor LIL-Stat (for LPS- and IL-l-inducible Stat; is consiitutively
expressed in CD34 early hematopoietic cells and in a large number of AML cases (chapter six) In
mature monocytes and granulocytes LIL-Stat cannot be detected, neither constitutive nor inducible
Based on recognition of the LIL-Stat protein by the antibody against he N-terminal site of Statl,
but not by the anti-StatlC-terminal ntibody, it can be hypothesized that LIL-Stat is transcribed
from the Statl gene followed by alternative splicing. For Statl and Stat3 alternatively spliced
isotbrrns have already been reported (StatlB and Stat3B. respectively) (.25,26) The StatlB isoform
(84 kDa) binds the DNA equally well as its wild- type, but it is transcriptionally inactive (25).
StatlB may compete with Statlcr for binding the GAS elements within promoters and block
transcriptional ctivation by Statlcr- Stat3B cDNA encodes a 83 kDa protein that has several
f 'eatures that are distinct from Stat3o (26) Stat3B. for instance, can functionallv interact with c-Jun,
whereas Stat3cr cannot (21) In these studies overexpression f Stat3B constitutively activated the
lL-(r-responsive element of the cr2-rnicroglobulin gene On the other hand, Stat3B has also been
decribed as a dominant negative regulator of I l-5-induced StatS-mediated transcription (26)
Recently. two naturally occurring truncated isoforms of IL-4-induced Stat6 were described. Stat6b
and Stat6c (28) Both Stat6b and Stat6c behave as dominant negative Stat6 variants. that affected
lL-4 rnediated responses through differential transcriptional regulation However, considering the
tbllowing observations it seerns unlikely that LIL-Stat is a carboxy-terminal truncated splice variant
of Stat I . ( i) LIL-Stat binds a gamrna interferon activation (GAS)-site which is different from the
GAS-site recognized by Statl In contrast, the splice variants StatlR, Stat3B. and the Stat6b and
Stat6c isoforms, bind GAS sequences also recognized by full length Statl, Stat3, and Stat6,
respectively (25.2'7,28) (i i) LIL-Stat is activated bv different cy'tokines than those which enhance
Statl activity. In contrast. StatlB. Stat3B. and Stat6a/b are activated by the same cfokines as the
wild type Statl, Stat3, and Stat6. respectively
LIL-Stat may also be the product of a novel gene possessing homology with the Statl arnino
terminus, as is the case for Stat-5A and Stat5B (29) Full length 96 kDa Stat5A and 94 kDa Stat5B
are activated by IL-5 and GM-CSF in immature. proliferating eosinophils and neutrophils (30)
During differentiation of these progenitors into mature eosinophils and neutrophils a shorler Stat5
protein is generated by a Stat5-cleaving protease, p80 Stat5 ln mature eosinophils and neutrophils
only this carboxy-terminal truncated isoforrn is preserrt. Sirnilar to StatlB, Stat3B, and Stat6b/c, p80
Stat5 is activated by the same cy'tokines that activate Stat5A/B Moreover. p80 Stat5 is
transcriptionallv inactive The presence of distinct Stat5 isoforms is also observed in nronocytes
(3 l) Freshly isolated monocpes expressed full length Stat5A and Stat5B and the p80 Stat5A
molecule in response to GM-CSF Monocytes differentiated into macrophages by cr.rlture in N4-
CSF, however. lost their abil ity to express p80 Stat5A protein The differential expressiorr of the
distinct Stat5 isoforms during hematopoietic differentiation suggests that these isotbrrns may
contribute to the activation ofunique biological responses such as proliferation and differentiation
In analogy with Stat3B. truncated Stat5 niay differentially regulate gene transcription by exefi ing a
dorninant-negative effect on the transcription of target genes or by interacting with other
transcription factors. Recently, the nucleus-associated protease was identif ied in earlv
hematopoietic cells that cleaves activated Stat5 to generate the truncated Stx5 R-forms (32). Sirnilar
to p80 Stat5, LL-Stat could be a proteolytic cleavage product of Statl Hower,'er. this seems
unlikely since, in contrast o p80 Stat5A, LIL-Stat is transcriptionallv active and is activated by
cytokines different from the cltokines rvhich enhance Statl activity
Several repofts have described the constitutive activit ion of Stat fhctors in cells of patients with
acute myeloid leukemia (AML) (23,24) Clonfocal microscopy. and band-shift assays combined
with specific antibody supershifts demonstrated constitutive nuclear localization. phosphorylation
and DNA-binding activity of Statl, Stat3, and Stat5 in a considerable number ol AML cases To
date, constitutive Stat activity is not l inked to increased proliferation of the AML blasts. norto FAB
classification However, several observations in other cell types indicate that constitutive Statl,
Stat3, and Stat5 activity in blasts of AML patients may regulate expression of celh"rlar genes that
participate in leukemogenesis (33-36)
ln analogy with LIL-Stat expression in early hematopoietic ells, CD34' cells and a leukemic
rnyeloid cell l ine previously shown to dit ' ferentiate in response to G-CSF. dernonstrated only the
activation of Stat3B in response to G-CSF- (37) Alternatively. in leukemic cells that were reported
not to differentiate in response to G-CSF both Stat3u and Stat3B were activated lt rnay be
hypothesized that activation of StatSrx may contribute to the lailure of sorne AN4[. cells to
dift 'erentiate in response to G-CSF The obsenation that LIL-Stat is absent in fully dift-erentiateo
cells suggests hat LIL-Stat may play a role in the differentiation process Once cells are sufl iciently
differentiated, LIL-Stat expression is suppressed which allows for terminal dif lerentiation If this
were the case, the presence of LIL-Stat in AN'IL cases nlay be an epiphenol.nenon a d represents he
stage at lvhich the AML clone was apprehendecl in its dit ' terentiation Alternativelv. constituti\,e
LIL-Stat expression in AML blasts may also be the result of aberrantly activated signaling
molecules Ongoing expression of LIL-Stat nray then render the immature hematopoietic cells
refractorl to differentiation Str.rdies rnay be undertaken to clone the LIL-Stat gene
The regulation of lL-6 gene expression is generally considered to be cell type and stimulus-
dependent In chapters seven, eight, nine and ten, we studied the IL-6 expression in human
monoc)'tes under various experimental conditions. In chapter seven. IL-.1 alone rvas incapable of
enhancing IL-6 mRNA expression, but synergized with LPS in regulating IL-6 transcript levels. At
the time it was speculated that increased DNA-binding of NF-IL6 combined with inhibited AP-l
binding rnay have resulted in enhanced IL-6 rnRNA levels However. it is now widely appreciated
that phosphorylation of the p65 subunit within the NF-xB conrplex may result in maxirnal
activation of NF-rB-driven gene transcription. without aflecting NF-KB DNA binding activity (38).
Alternatively, binding of cofactors may enhance NF-rB transcriptional potency (39,40) It may be
postulated that lL-3. although alone incapable of activating NF-rB, may synergize with LPS
through the phosphorylation of p6-5 or other regulatorn factors. In chapters nine and ten we
identif led the involvement of the ERKI/2 and JNK pathways in mediating the transcriptional
activitv of NF-rB While LPS triggers NF-rB DNA binding, lL-3 may maximize NF-xB-driven
promoter activity through the activation of the ERKI/2 andlor JNK pathrvay In this respect, it was
recently demonstrated that LPS enhances NF-rB DNA binding through the activation of the Ixts
kinases (lKKs) in hurnan monocltes (41) In particular IKKB activity was enhanced bv LPS
Another tool in studying the involvement of the different signaling pathways in mediating IL-6
expression is the use of the serine/threonine protein phosphatase inhibitor okadaic acid (OA)
ln chapters nine and ten the Raf-I,MEKl/ERKl/2 and MEKKI,MKK4/JNK pathways were
shown to be involved in OA-rnediated IL-6 
-qene transcription. ln particular, both pathways
significantly enhanced NF-rB activation. The activation of NF-rB is regarded to be crucial for the
regulation of immune and inflammatory responses (42, 43') Most importantly, NF-rB has been
shor.vn to be a crit ical transcription factor for the production of cyokines and adhesion molecules
involved in these responses (39. . l i . 44) An exageerated activation of NF-rB can lead to the
uncontrolled expression of NF-rB-responsive products and contribute to the pathogenesis of a
number of disease processes Septic shock, for instance, is induced by the bacterial cell wall
breakdown product LPS that generates numerous endogenous mediators. such as IL-6, tL-1, and
TNF-o. (45) The expression of these mediators in septic shock has been linked to NF-rB activation
In fbct. nuclear extracts frorn peripheral blood rnononuclear cells from non-surviving patients with
septic shock demonstrate increased nuclear binding activity of NF-rB compared with survivors
(46) lncreased NF-xB activation is also correlated with increased local concentrations oflL-6. IL-
l. and TNF-o in alveolar macrophages lioni patients with adult respiratory distress yndrome (47)
ln the pathogenesis of rheumatoid arthrit is (RA), the release of inflamrnatory mediators is induced
by the overexpression of inflamrnatory cy.tokines, primarily released from macrophages (43) NF-
xB act ivat ion is  undoubtedlv involved in the pathogenesis of  RA. s ince i t  b inds in  the prornoters
and enhancers of the cyokines Moreover. NF-rB induction of II--l and TNF-cr rnav perpetuate he
) J-,
disease by enhancing the positive feedback loop, resulting in ongoing activation of NF-xB-
mediated gene expression The inhibition of NF-rB activation is a poterrtial therapeutic strategy to
treat immune and inflammatory diseases (43) Some pharmacologic agents that supress NF-rB
activity include glucocorticoids (e.g dexamethasone and prednisone)(a8). immunosuppressants
(e g cyclosporine)(49), and non-steroidal anti inflammatory drugs (NSAIDs) (e g aspirin)(50)
However, the exact mechanism by which many of these agents inhibit NF-xB activity is not clearly
known. The efficiency of these agerrts is diminished bv their non-specific effect on NF-rB
activation The identif ication of specific components of the signaling pathways leading to NF-xB
activation and the induction cytokine gene expression may form the basis for development of new
anti-infl ammatory agents
In contrast to the ERKI/2 and JNK pathways, the p38 Il, lAP kinase pathway did not affect IL-6
promoter activity, but rather enhanced IL-6 protein secretion by stabil izing lL-6 tlanscripts ln
previous reports the p38 pathway was implicated in enhancins translation of the IL-lB and TNF-cr
t ranscr ipts(5 1,52)  Blockingthep3SMAPkinasepathwaymaysuppresscyokineprote insecret ion
in numerous cell types. albeit at distinct levels
ln chapter eleven it was shown that M--rB activation in the erythroleukemic cell l ine TF-l is
regulated independently of the pl8 MAP kinase pathway, whereas in previous chapters we
identif ied the involvement of the ERKI/2 and JNK pathways in activating NF-KB transcriptional
activity
The importance of recognizing signaling pathways involved in NF-xB activation is based on the
observation that NF-rB protects the cell from programmed cell death (apoptosis) in numerous cell
systems (53-55) ln AML, the sensitivity of the cells to chemotherapeutic agents depends on their
intrinsic or acquired resistance to init iate apoptosis in resopnse to therapeutic insult (56, 57)
Besides the expression of genes that are involved in multi-drug resistance. additional parameters are
relevant forthe final cfotoxic response. an important one of which is bcl-2 (58-60) The bcl-2 gene
encodes a mitochondrial protein that inhibits the onset ofapoptosis by growth factor rvithdrawal or
c)'totoxic agents In a number of clinical studies high bcl-2 expression has been associated with a
low complete remission rate and poor sufl/ival in AML However. irt vitro studies with 4l AIVIL
samples collected at disease onset showed relatively low levels of basal apoptosis (0-5%) in the
presence, but also in the absence of bcl-2 overexpression (61) This would suggest hat other
mechanisms are also involved in the regulation of apoptosis and thus treatment effrcacy One such a
mechanisnt may be the presence olactivated NF-rB Activated NF-rB renders cells less vulnerable
to the effects of cy'totoxic agents by inducing anti-apoptotic genes, such as the inhibitor-of-
apoptosis proteins c-lAPl and c-lAP2 (62) A role for NF-rB in preventing apoptosis has clearly
been demonstrated in B cell l ines (63) These cell l ines constitutively express active NF-xB. and
inactivation of the factor induces apoptosis Thus. in B cells. constitutive active NF-rcB has a role in
ensuring cell sun,ival In a different study it was demonstrated that not only TNF-s.-induced. but
also chernotherapy-induced apoptosis is potentiated in cells with inactivated NF-rB (64) DNA-
damaging agents. such as daunorubicin, which can activate NF-rcB, were more toxic to cel ls when
NF-KII activation was blocked by the expression of a dominant-negative kB-cr mutant
In chapter three consti tut ively enhanced DNA binding activi tv of NF-rB was found in 30-40% of
the AML cases ln these cases ongoing NF-rB DNA binding could not be inhibited by anti-
interleukin-l  antibody, suggesting an IL-l- independent act ivat ion. Since Ras mutations, which are
detected in 30-40% of the AML cases, activate the Raf-1,MEK/ERK pathway, this oncogene may
be a candidate involved in el ici t ing consti tut ive NF-rB activi ty in AML (65) Enhanced activi ty of
NF-KB in AML cel ls may also be noticed as result of paracrine cel l  act ivat ion by cy.tokines
It may be postulated that suppression of NF-rB activi ty, ibr example by pharmacological inhibitors,
in AML cells may have positive effects with respect to the cyotoxicity of chemotherapeutic agents
Future studies should reveal relevance of consti tut ive NF-rB activi ty in AML and the possible
benefi t  of suppressing NF-KB activi ty on chemotherapv-induced cl. totoxicitv
ln conclusion, these studies have considerably contr ibuted to our understanding of cy.tokine gene
regulat ion in both healthy monocv'tes and acute myeloid leukemia cel ls. The great complexity of
cl4okine gene expression in hernatopoiet ic cel ls and the rnarrv questions st i l l  to be answered
encourage us to further explore the underlying rnechanisms o1'AML prol i ferat ion.
FUTUR-E PERSPECTTvES
In the present thesis studies were undertaken to understand the regulat ion of cytokine gene
expression in rnonocy'tes and acute myeloid leukemia cel ls. Part icular attention was paid to the
tr iggers of cytokine production, to the transduction pathways leading to cytokine expression and
to the transcript ion factors responsible for cy'tokine gene regulat ion. The studies described in this
thesis have considerably contr ibuted to our understanding of normal and aberrant cy'tokine gene
requlat ion. Some questions \!ere answered. sorne hypotheses were tested, and in return rnore
interesting questions and hypotheses have arisen I feel,  horvever, that a few l ines of investigation
deserve particular attention in the future
First lv. focus should be directed towards the cloning and characterization of the novel transcript ion
tactor LIL-Stat LIL-Stat nray be relevant tbr the dif ferentiat ion of henratopoiet ic cel ls, and i ts
characterization may have irnportant consequences for the understanding of henratopoiet ic
developrnent and the onset of leukemogenesis Since AML blasts are characterized by a
differentiat ion-block. the identi f icat ion of factors inducing or apprehending dif ferentiat ion may be
of great cl inical impor-tance LIL-STAT may turn out to be a transcript ion factor aft-ect ing
dif ' ferentiat ion lnduction or inhibit ion of LIL-Stat mav fbrce the AML blast to terminal lv
dif lerentiate. thus dimini shing turnorigeneity.
Secondlv, the role of ongoing NF-xB activi ty in AMt. may be fur-ther explored A recent pi lot study
sLrqgested that therapy outconle of AML patients correlated well  with the percentase of i t t  vi ln,
apoptotic blasts, and. rnore importantly, that spontaneous apoptosis of AML blasts served as a good
prognostic factor for cl inical outcome (66) In view of these data i t  is a chal lenge to determine
whether NF-xB activi ty may contr ibute to intr insic or acquired resistance in AML. Furthernrore, the
mechanism of constitgtive NF-xB activity in AML rnay be the object of further investigation. We
demonstrated that NF-rB transcriptional potency is dependent on serine phosphorylation but also
on the presence of the c-Jun protein Further upstream it was shown that both the ERK and JNK
pathways are involved in enhancing NF-KB activity Future studies may reveal whether enhanced
M-KB transcriptional activity in AML is the result of autocrine/or paracrine loops by other
cy,tokines or growth factors. such as lL-6 or GM-CSF or due to mutation in the Ras gene resulting
in the continuous activation of the Raf/MEK/ERK pathway Alternatively, other rnodr;les Llpstream
from NF-rB, such as Rac. IL-l receptor associated kinase (IRAK), TNF-receptor associated t-actor
6 (TRAF6). NF-rB-inducing kinase (NIK) or lxB kinase (lKK) may be constitutively activated.
resulting in enhanced NF-rB DNA binding or transcriptional ctivity The identif ication of NF-rB
as an anti-apoptotic signal in a AML may lead to the interesting consequence that blocking of the
NF-KB mediated activation may result in an increase in the susceptibility of the blasts to cltotoxlc
st imul i  and thus an improved c l in ica l  progrros is
Future studies may further reveal the involvement of triggers, transduction molecules. and
transcripion factors in normai and disregulated cyokine gene transcription Comprehension of the
highly developed state of intricacy of these phenomena wil l allow the pursuit of new strategies in
the treatment of acute mveloid leukemia nd inflammatory disorders
